CV Sciences (CVSI) Cash from Operations Growth (3y) (2014 - 2026)
CV Sciences (CVSI) Cash from Operations Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.51 Bn | 30.57 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | 27.85% |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn | -53.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.04% |
| Dec 31, 2025 | -50.79% |
| Sep 30, 2025 | 17.60% |
| Jun 30, 2025 | 30.95% |
| Mar 31, 2025 | 40.21% |
| Dec 31, 2024 | 47.96% |
| Sep 30, 2024 | 57.31% |
| Jun 30, 2024 | 73.50% |
| Mar 31, 2024 | 32.56% |
| Dec 31, 2023 | 57.34% |
| Sep 30, 2023 | 77.76% |
| Jun 30, 2023 | 37.24% |
| Mar 31, 2023 | 37.09% |
| Dec 31, 2022 | 26.94% |
| Sep 30, 2022 | 19.74% |
| Jun 30, 2022 | -34.51% |
| Mar 31, 2022 | -35.69% |
| Dec 31, 2021 | -34.66% |
| Sep 30, 2021 | -32.84% |
| Jun 30, 2021 | -41.36% |